An observational study in Infertility and IVF, sponsored by Clinique Ovo. Completed at 1 site in Canada. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-02-20.
Sponsored by Clinique Ovo · Observational
Follitropin delta (Rekovelle) algorithm established by Ferring provides personalized gonadotrophin doses based on each patient's weight and AMH. As a result, risks of stimulation failure or ovarian hyperstimulation syndrome (OHSS) during an in vitro fertilization (IVF) cycle are minimized.
As a standard practice for OHSS prevention at clinique ovo, women undergoing IVF will have a scheduled ultrasound and blood test on the sixth day of their stimulation treatment. However, with the determination of the Rekovelle and Menopur algorithm, the risks of OHSS before the tenth day have been considerably minimized.
The purpose of this study is to evaluate the necessity of programming an ultrasound and blood test prior to the tenth day of ovarian stimulation when women are on personalized doses of Rekovelle and Menopur duting an antagonist IVF cycle. Based on the results of the analysis, we will assess the economic impact that programming an ultrasound and blood test at day 10 might have.
2,506 studies on the registry are indexed under Infertility; 407 are open to participants now.
This study's enrollment of 772 is above the median of 200 across 714 observational studies indexed under Infertility.
Browse Infertility studies →Clinique Ovo is the lead sponsor of 35 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Women consulting the clinic for fertility issues that require in vitro fertilization
Exclusion Criteria:
Women undergoing an antagonist in vitro fertilization cycle using Rekovelle and Menopur for stimulation
Other: Study chart review
Evaluation of the IVF cycle using the prescribed medication
Identify the population where a simplified IVF monitoring is conceivable
Rate of Rekovelle and / or Menopur dose modification before day 10 ultrasound
Time frame: Up to 3 weeks
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Clinique Ovo